A Phase 2 interventional study of Filgotinib and Placebo in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis, sponsored by Galapagos NV. Completed at 71 sites in 8 countries. Open to male participants aged 21 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-04-30.
Sponsored by Galapagos NV · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies testing GLPG0634 in Arthritis, Rheumatoid — 4 open to participants now, 4 under way, none of them phase 3. GLPG0634 · Arthritis, Rheumatoid.
Among the 17 studies testing GLPG0634 in Arthritis, Rheumatoid, this one is the 10th largest by enrollment, is the only one that started in 2019, is one of 6 in phase 2, and was the 11th registered.
3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.
Browse Arthritis, Rheumatoid studies →4 of the 17 studies testing GLPG0634 in Arthritis, Rheumatoid are open now, in 3 countries. Recruiting first, the newest first:
University Hospital, Toulouse · Sites in France
Ages 18–65
Universita di Verona · Sites in Italy
Ages 18–65
R.Bos · Sites in Netherlands
Ages 18–101
Leiden University Medical Center · Sites in Netherlands
Ages 18+
By country, each count listing its studies:
GLPG0634: first EMA approval 2020. What it is approved for, and how studies give it, is on its page →
Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 21 Years to 65 Years · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
First in 2011; this study’s year is marked. 1 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 109 is above the median of 96 across 2,222 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 287 across the 17 interventional studies. Of the 12 that completed or were terminated, 10 (83%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 17 have an industry lead sponsor. The 8 most frequent:
This study is registered under Galapagos NV, one of the names counted as Lakefront Biotherapeutics NV. Under that name alone:
Galapagos NV is the lead sponsor of 103 studies on the registry; none are open to participants now.
Of its 14 completed or terminated interventional studies of FDA-regulated products, 11 (79%) have results posted.
Lakefront Biotherapeutics NV has 8 studies filed under Arthritis, Rheumatoid — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 17 studies testing GLPG0634 in Arthritis, Rheumatoid, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is to evaluate the effect of filgotinib on semen parameters in adult males with active rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, or non-radiographic axial spondyloarthritis.
Results of this study may be pooled with the results of a separate study being conducted in participants with inflammatory bowel disease (Protocol GS-US-418-4279; NCT03201445) with the same objective.
Key Inclusion Criteria:
Key Exclusion Criteria:
Note: Other protocol-defined Inclusion/Exclusion criteria may apply.
Participants received filgotinib 200 milligrams (mg) tablet, orally, once daily up to Week 13 in the double-blind (DB) phase. At Week 13, participants who were arthritis responders, were unblinded and received open-label (OL) treatment filgotinib 200 mg, tablet, orally, once daily up to approximately 143 weeks (until Week 156) in the extension (EXT) phase and participants who were arthritis nonresponders discontinued blinded study drug and started standard of care (SOC) treatment in the EXT phase. Participants on DB treatment or OL filgotinib who entered the monitoring phase (if their sperm parameters met ≥50% decrease threshold in pre-specified semen parameters) discontinued the study drug and started SOC for up to 52 weeks.
Drug: Filgotinib · Drug: Standard of Care
Participants received placebo (matched to filgotinib) tablet, orally, once daily up to Week 13 in the DB phase. At Week 13, participants were unblinded and started SOC treatment in the EXT phase for up to approximately 143 weeks (until Week 156). Participants who entered the monitoring phase (if their sperm parameters met ≥50% decrease threshold in pre-specified semen parameters) continued on SOC treatment.
Drug: Placebo · Drug: Standard of Care
200-mg tablet administered orally once daily
Also known as: GS-6034, Jyseleca®
Placebo to match filgotinib tablet administered orally once daily
Locally approved treatment, accepted by medical experts as a proper treatment for rheumatic conditions, prescribed according to best clinical practice, with no known testicular toxicity.
Percentage of Participants With a ≥ 50% Decrease From Baseline in Sperm Concentration at Week 13
Baseline for sperm/semen parameters was the mean of 2 evaluable semen samples at screening. The normal range for sperm concentration is ≥15 million sperms/mL. Percentage change = (\[mean at Week 13 - baseline\] / baseline) × 100; value at Week 13 was the mean of 2 evaluable samples collected at Week 13.
Time frame: Baseline to Week 13
Percentage of Participants With a ≥ 50% Decrease From Baseline in Sperm Concentration at Week 26
Arthritis responder: For rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS), and non-radiographic axial spondyloarthritis (nrAxSpA), a participant with an improvement in the Physician's Global Assessment of Disease Activity (PhGADA) of at least 20% compared with baseline (Day 1) at the specified assessment time. Arthritis nonresponder: For RA, PsA, AS, or nrAxSpA, a participant who did not fulfill the definition of arthritis responder at the specified assessment timepoint. PhGADA: Physician measured the participant's disease severity on a visual analogue scale (VAS) ranged from 0 (no disease)-100 (worst disease) millimeters (mm). Baseline value for sperm/semen parameters was the mean of 2 evaluable semen collections at the screening visit. The normal range for sperm concentration is ≥15 million sperms/mL. Percentage change = (\[mean at Week 26 - baseline\] / baseline) × 100; value at Week 26 was the mean of 2 evaluable samples collected at Week 26.
Time frame: Baseline to Week 26
Change From Baseline in Sperm Total Motility at Week 13
The normal range for sperm total motility is ≥40%.
Time frame: Baseline, Week 13
Change From Baseline in Sperm Total Motility at Week 26
Arthritis responder: For RA, PsA, AS, and nrAxSpA, a participant with an improvement in the PhGADA of at least 20% compared with baseline (Day 1) at the specified assessment time. Arthritis nonresponder: For RA, PsA, AS, or nrAxSpA, a participant who did not fulfill the definition of arthritis responder at the specified assessment timepoint. PhGADA: Physician measured the participant's disease severity on a VAS ranged from 0 (no disease)-100 (worst disease) mm. The normal range for sperm total motility is ≥40%.
Time frame: Baseline, Week 26
Change From Baseline in Total Sperm Count at Week 13
The normal range for total sperm count is ≥ 39 million sperms/ejaculate.
Time frame: Baseline, Week 13
Change From Baseline in Total Sperm Count at Week 26
Arthritis responder: For RA, PsA, AS, and nrAxSpA, a participant with an improvement in the PhGADA of at least 20% compared with baseline (Day 1) at the specified assessment time. Arthritis nonresponder: For RA, PsA, AS, or nrAxSpA, a participant who did not fulfill the definition of arthritis responder at the specified assessment timepoint. PhGADA: Physician measured the participant's disease severity on a VAS ranged from 0 (no disease)-100 (worst disease) mm. The normal range for total sperm count is ≥ 39 million sperms/ejaculate.
Time frame: Baseline, Week 26
Change From Baseline in Sperm Concentration at Week 13
The normal range for sperm concentration is ≥15 million sperms/mL.
Time frame: Baseline, Week 13
Change From Baseline in Sperm Concentration at Week 26
Arthritis responder: For RA, PsA, AS, and nrAxSpA, a participant with an improvement in the PhGADA of at least 20% compared with baseline (Day 1) at the specified assessment time. Arthritis nonresponder: For RA, PsA, AS, or nrAxSpA, a participant who did not fulfill the definition of arthritis responder at the specified assessment timepoint. PhGADA: Physician measured the participant's disease severity on a VAS ranged from 0 (no disease)-100 (worst disease) mm. The normal range for sperm concentration is ≥15 million sperms/mL.
Time frame: Baseline, Week 26
Change From Baseline in Ejaculate Volume at Week 13
The normal range for ejaculate volume is ≥1.5 mL.
Time frame: Baseline, Week 13
Change From Baseline in Ejaculate Volume at Week 26
Arthritis responder: For RA, PsA, AS, and nrAxSpA, a participant with an improvement in the PhGADA of at least 20% compared with baseline (Day 1) at the specified assessment time. Arthritis nonresponder: For RA, PsA, AS, or nrAxSpA, a participant who did not fulfill the definition of arthritis responder at the specified assessment timepoint. PhGADA: Physician measured the participant's disease severity on a VAS ranged from 0 (no disease)-100 (worst disease) mm. The normal range for ejaculate volume is ≥1.5 mL.
Time frame: Baseline, Week 26
Change From Baseline in Percent Normal Sperm Morphology at Week 13
The normal range for percent normal sperm morphology is ≥30% normal sperms.
Time frame: Baseline, Week 13
Change From Baseline in Percent Normal Sperm Morphology at Week 26
Arthritis responder: For RA, PsA, AS, and nrAxSpA, a participant with an improvement in the PhGADA of at least 20% compared with baseline (Day 1) at the specified assessment time. Arthritis nonresponder: For RA, PsA, AS, or nrAxSpA, a participant who did not fulfill the definition of arthritis responder at the specified assessment timepoint. PhGADA: Physician measured the participant's disease severity on a VAS ranged from 0 (no disease)-100 (worst disease) mm. The normal range for percent normal sperm morphology is ≥30% normal sperms.
Time frame: Baseline, Week 26
Participants were enrolled at study sites in Bulgaria, Czech Republic, Estonia, Georgia, Latvia, Poland, Spain, and Ukraine. The first participant was screened on 28 May 2019. A total of 308 participants were screened of which 109 participants were randomized into the study.
| Milestone | Filgonitib | Placebo |
|---|---|---|
| Started | 54 | 55 |
| Completed | 54 | 53 |
| Not completed | 0 | 2 |
| Withdrew: Withdrawal by subject | 0 | 2 |
| Milestone | Filgonitib | Placebo |
|---|---|---|
| Started | 46 | 49 |
| Completed | 24 | 26 |
| Not completed | 22 | 23 |
| Withdrew: Adverse event | 5 | 1 |
| Withdrew: Pre-specified decrease in sperm parameters | 16 | 17 |
| Withdrew: Withdrawal by subject | 1 | 3 |
| Withdrew: Physician decision | 0 | 2 |
| Milestone | Filgonitib | Placebo |
|---|---|---|
| Started | 27 | 21 |
| Completed | 27 | 20 |
| Not completed | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 1 |
Baseline for sperm/semen parameters was the mean of 2 evaluable semen samples at screening. The normal range for sperm concentration is ≥15 million sperms/mL. Percentage change = (\[mean at Week 13 - baseline\] / baseline) × 100; value at Week 13 was the mean of 2 evaluable samples collected at Week 13.
| percentage of participants | Filgonitib | Placebo |
|---|---|---|
| Percentage of Participants With a ≥ 50% Decrease From Baseline in Sperm Concentration at Week 13 | 13.0 | 7.5 |
Arthritis responder: For rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS), and non-radiographic axial spondyloarthritis (nrAxSpA), a participant with an improvement in the Physician's Global Assessment of Disease Activity (PhGADA) of at least 20% compared with baseline (Day 1) at the specified assessment time. Arthritis nonresponder: For RA, PsA, AS, or nrAxSpA, a participant who did not fulfill the definition of arthritis responder at the specified assessment timepoint. PhGADA: Physician measured the participant's disease severity on a visual analogue scale (VAS) ranged from 0 (no disease)-100 (worst disease) millimeters (mm). Baseline value for sperm/semen parameters was the mean of 2 evaluable semen collections at the screening visit. The normal range for sperm concentration is ≥15 million sperms/mL. Percentage change = (\[mean at Week 26 - baseline\] / baseline) × 100; value at Week 26 was the mean of 2 evaluable samples collected at Week 26.
| percentage of participants | Filgotinib/OL Filgotinib (Responder) | Placebo/SOC (Responder) | Filgotinib/SOC (Nonresponder) | Placebo/SOC (Nonresponder) |
|---|---|---|---|---|
| Percentage of Participants With a ≥ 50% Decrease From Baseline in Sperm Concentration at Week 26 | 10.3 | 8.0 | 14.3 | 0 |
The normal range for sperm total motility is ≥40%.
| percentage of motile sperms | Filgonitib | Placebo |
|---|---|---|
| Change From Baseline in Sperm Total Motility at Week 13 | -2.3 (-8.1 to 1.4) | -1.7 (-5.8 to 0.7) |
Arthritis responder: For RA, PsA, AS, and nrAxSpA, a participant with an improvement in the PhGADA of at least 20% compared with baseline (Day 1) at the specified assessment time. Arthritis nonresponder: For RA, PsA, AS, or nrAxSpA, a participant who did not fulfill the definition of arthritis responder at the specified assessment timepoint. PhGADA: Physician measured the participant's disease severity on a VAS ranged from 0 (no disease)-100 (worst disease) mm. The normal range for sperm total motility is ≥40%.
| percentage of motile sperms | Filgotinib/OL Filgotinib (Responder) | Placebo/SOC (Responder) | Filgotinib/SOC (Nonresponder) | Placebo/SOC (Nonresponder) |
|---|---|---|---|---|
| Change From Baseline in Sperm Total Motility at Week 26 | -2.4 (-9.3 to 1.0) | 0.9 (-5.2 to 6.3) | -1.4 (-13.3 to 13.0) | -2.8 (-8.5 to 2.9) |
The normal range for total sperm count is ≥ 39 million sperms/ejaculate.
| million sperms/ejaculate | Filgonitib | Placebo |
|---|---|---|
| Change From Baseline in Total Sperm Count at Week 13 | -2.1 (-41.7 to 31.0) | -9.6 (-36.2 to 18.0) |
Arthritis responder: For RA, PsA, AS, and nrAxSpA, a participant with an improvement in the PhGADA of at least 20% compared with baseline (Day 1) at the specified assessment time. Arthritis nonresponder: For RA, PsA, AS, or nrAxSpA, a participant who did not fulfill the definition of arthritis responder at the specified assessment timepoint. PhGADA: Physician measured the participant's disease severity on a VAS ranged from 0 (no disease)-100 (worst disease) mm. The normal range for total sperm count is ≥ 39 million sperms/ejaculate.
| million sperms/ejaculate | Filgotinib/OL Filgotinib (Responder) | Placebo/SOC (Responder) | Filgotinib/SOC (Nonresponder) | Placebo/SOC (Nonresponder) |
|---|---|---|---|---|
| Change From Baseline in Total Sperm Count at Week 26 | -0.2 (-39.5 to 44.5) | 16.8 (-49.3 to 60.6) | 32.2 (-60.8 to 121.3) | -29.9 (-79.8 to 36.6) |
The normal range for sperm concentration is ≥15 million sperms/mL.
| million sperms/mL | Filgonitib | Placebo |
|---|---|---|
| Change From Baseline in Sperm Concentration at Week 13 | 3.7 (-7.2 to 13.1) | -0.4 (-6.1 to 7.8) |
Arthritis responder: For RA, PsA, AS, and nrAxSpA, a participant with an improvement in the PhGADA of at least 20% compared with baseline (Day 1) at the specified assessment time. Arthritis nonresponder: For RA, PsA, AS, or nrAxSpA, a participant who did not fulfill the definition of arthritis responder at the specified assessment timepoint. PhGADA: Physician measured the participant's disease severity on a VAS ranged from 0 (no disease)-100 (worst disease) mm. The normal range for sperm concentration is ≥15 million sperms/mL.
| million sperms/mL | Filgotinib/OL Filgotinib (Responder) | Placebo/SOC (Responder) | Filgotinib/SOC (Nonresponder) | Placebo/SOC (Nonresponder) |
|---|---|---|---|---|
| Change From Baseline in Sperm Concentration at Week 26 | 1.7 (-8.9 to 21.2) | 9.6 (-3.7 to 29.0) | 10.3 (-43.5 to 36.3) | -5.8 (-12.9 to 4.6) |
The normal range for ejaculate volume is ≥1.5 mL.
| mL | Filgonitib | Placebo |
|---|---|---|
| Change From Baseline in Ejaculate Volume at Week 13 | -0.3 (-0.6 to 0.1) | -0.2 (-0.4 to 0.1) |
Arthritis responder: For RA, PsA, AS, and nrAxSpA, a participant with an improvement in the PhGADA of at least 20% compared with baseline (Day 1) at the specified assessment time. Arthritis nonresponder: For RA, PsA, AS, or nrAxSpA, a participant who did not fulfill the definition of arthritis responder at the specified assessment timepoint. PhGADA: Physician measured the participant's disease severity on a VAS ranged from 0 (no disease)-100 (worst disease) mm. The normal range for ejaculate volume is ≥1.5 mL.
| mL | Filgotinib/OL Filgotinib (Responder) | Placebo/SOC (Responder) | Filgotinib/SOC (Nonresponder) | Placebo/SOC (Nonresponder) |
|---|---|---|---|---|
| Change From Baseline in Ejaculate Volume at Week 26 | -0.2 (-0.7 to 0.4) | -0.6 (-0.7 to -0.2) | 0.2 (-1.0 to 1.1) | -0.3 (-0.6 to 0.2) |
The normal range for percent normal sperm morphology is ≥30% normal sperms.
| percentage of normal sperms | Filgonitib | Placebo |
|---|---|---|
| Change From Baseline in Percent Normal Sperm Morphology at Week 13 | 1 (-1 to 2) | 1 (-1 to 3) |
Arthritis responder: For RA, PsA, AS, and nrAxSpA, a participant with an improvement in the PhGADA of at least 20% compared with baseline (Day 1) at the specified assessment time. Arthritis nonresponder: For RA, PsA, AS, or nrAxSpA, a participant who did not fulfill the definition of arthritis responder at the specified assessment timepoint. PhGADA: Physician measured the participant's disease severity on a VAS ranged from 0 (no disease)-100 (worst disease) mm. The normal range for percent normal sperm morphology is ≥30% normal sperms.
| percentage of normal sperms | Filgotinib/OL Filgotinib (Responder) | Placebo/SOC (Responder) | Filgotinib/SOC (Nonresponder) | Placebo/SOC (Nonresponder) |
|---|---|---|---|---|
| Change From Baseline in Percent Normal Sperm Morphology at Week 26 | 1 (-2 to 5) | 3 (-2 to 8) | 3 (-15 to 6) | 4 (1 to 8) |
Collected over From first dose up to Week 156. TEAEs were considered as AEs with onset on or after the first dose of study drug to the last dose + 30 days. AEs leading to premature discontinuation study drug was also a TEAE.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Double-Blind Phase: Filgotinib 200 mg | 0/54 (0%) | 2/54 (3.7%) | 12/54 (22.2%) |
| Double-Blind Phase: Placebo | 0/55 (0%) | 1/55 (1.8%) | 10/55 (18.2%) |
| Extension Phase: Placebo - SOC | 0/49 (0%) | 2/49 (4.1%) | 23/49 (46.9%) |
| Extension Phase: Filgotinib 200 mg - SOC | 0/7 (0%) | 1/7 (14.3%) | 5/7 (71.4%) |
| Extension Phase: Filgotinib 200 mg - OL Filgotinib 200 mg | 0/39 (0%) | 5/39 (12.8%) | 20/39 (51.3%) |
| Event | Double-Blind Phase: Filgotinib 200 mg | Double-Blind Phase: Placebo | Extension Phase: Placebo - SOC | Extension Phase: Filgotinib 200 mg - SOC | Extension Phase: Filgotinib 200 mg - OL Filgotinib 200 mg |
|---|---|---|---|---|---|
| AppendicitisInfections and infestations | 0/54 | 0/55 | 0/49 | 1/7 | 0/39 |
| Meniscus injuryInjury, poisoning and procedural complications | 0/54 | 0/55 | 2/49 | 0/7 | 0/39 |
| Lower limb fractureInjury, poisoning and procedural complications | 0/54 | 0/55 | 0/49 | 0/7 | 1/39 |
| RadiculopathyNervous system disorders | 0/54 | 0/55 | 0/49 | 0/7 | 1/39 |
| UveitisEye disorders | 0/54 | 0/55 | 0/49 | 0/7 | 1/39 |
| NephrolithiasisRenal and urinary disorders | 0/54 | 0/55 | 0/49 | 0/7 | 1/39 |
| Intervertebral disc disorderMusculoskeletal and connective tissue disorders | 0/54 | 0/55 | 0/49 | 0/7 | 1/39 |
| COVID-19 pneumoniaInfections and infestations | 0/54 | 0/55 | 0/49 | 0/7 | 1/39 |
| Ligament ruptureInjury, poisoning and procedural complications | 0/54 | 0/55 | 1/49 | 0/7 | 0/39 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 1/54 | 0/55 | 0/49 | 0/7 | 0/39 |
| Event | Double-Blind Phase: Filgotinib 200 mg | Double-Blind Phase: Placebo | Extension Phase: Placebo - SOC | Extension Phase: Filgotinib 200 mg - SOC | Extension Phase: Filgotinib 200 mg - OL Filgotinib 200 mg |
|---|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 4/54 | 4/55 | 3/49 | 4/7 | 2/39 |
| COVID-19Infections and infestations | 0/54 | 0/55 | 10/49 | 3/7 | 6/39 |
| Drug hypersensitivityImmune system disorders | 0/54 | 0/55 | 0/49 | 1/7 | 0/39 |
| Seasonal allergyImmune system disorders | 0/54 | 0/55 | 0/49 | 1/7 | 1/39 |
| Rhinitis allergicRespiratory, thoracic and mediastinal disorders | 0/54 | 0/55 | 0/49 | 1/7 | 0/39 |
| Sleep apnoea syndromeRespiratory, thoracic and mediastinal disorders | 0/54 | 0/55 | 0/49 | 1/7 | 0/39 |
| Alanine aminotransferase increasedInvestigations | 0/54 | 0/55 | 2/49 | 1/7 | 1/39 |
| HeadacheNervous system disorders | 2/54 | 1/55 | 2/49 | 1/7 | 2/39 |
| SciaticaNervous system disorders | 0/54 | 0/55 | 1/49 | 1/7 | 0/39 |
| External ear painEar and labyrinth disorders | 0/54 | 0/55 | 0/49 | 1/7 | 0/39 |
The Safety Analysis Set included all randomized participants who took ≥ 1 dose of double-blind study drug.
| Age, Continuous(years) | Filgonitib | Placebo | Total |
|---|---|---|---|
| Mean | 40 ± 8.5 | 39 ± 7.8 | 40 ± 8.1 |
| Sex: Female, Male(Participants) | Filgonitib | Placebo | Total |
|---|---|---|---|
| Female | 0 | 0 | 0 |
| Male | 54 | 55 | 109 |
| Ethnicity (NIH/OMB)(Participants) | Filgonitib | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 1 | 0 | 1 |
| Not Hispanic or Latino | 53 | 55 | 108 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Filgonitib | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 54 | 55 | 109 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Sperm Concentration(million sperms/milliliter (mL)) | Filgonitib | Placebo | Total |
|---|---|---|---|
| Mean | 71.2 ± 41.00 | 66.9 ± 38.72 | 69.0 ± 39.74 |
| Total Sperm Count(million sperms/ejaculate) | Filgonitib | Placebo | Total |
|---|---|---|---|
| Mean | 208.4 ± 136.94 | 225.2 ± 137.39 | 216.9 ± 136.79 |
| Sperm Total Motility(percentage of motile sperm) | Filgonitib | Placebo | Total |
|---|---|---|---|
| Mean | 55.9 ± 8.99 | 58.2 ± 8.48 | 57.1 ± 8.77 |
| Ejaculate Volume(mL) | Filgonitib | Placebo | Total |
|---|---|---|---|
| Mean | 3.1 ± 1.26 | 3.5 ± 1.29 | 3.3 ± 1.29 |
1 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from May 2019 to primary completion in Aug 2020, 14 months.
Results were first posted in Aug 2023, 2 years 11 months after primary completion. A results delay was requested in Jul 2021.
Of 116 industry-sponsored phase 2 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 24. This study's 14 months is below that.
Counting every sponsor, half of 158 studies reached it within 18 months; a quarter within 13 and three quarters within 30.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: GLPG0634